Ibrutinib is a first-in-class
Bruton's tyrosine kinase inhibitor, which works by forming a strong covalent bond with BTK to block the transmission of cell survival signals within the malignant B-cells.
Screening of genomic DNA to identify mutations in the gene for
Bruton's tyrosine kinase. Hum Mol Genet.
They further propose that
Bruton's tyrosine kinase might serve as a mediator of lipopolysaccharide-induced dendritic cell maturation and macrophage polarisation and highlight that several studies have reported an increase in alveolar infiltration of T helper 2 proinflammatory cytokines in Bruton's tyrosine kinase-deficient mice, which results in airway inflammation [19, 20].
Bruton's tyrosine kinase (Btk) is a member of the Tec family of kinases and the only known one associated with human disease [1,2].
Singapore scientists from Bioprocessing Technology Institute (BTI) under the Agency of Science, Technology and Research (A*STAR) found that this 'switch' called
Bruton's tyrosine kinase (BTK) when turned on, activates the production of interferons - a potent class of virus killers that enables the body to fight harmful pathogens such as dengue and influenza viruses.
Phospholipase C-gamma 2 couples
Bruton's tyrosine kinase to the NF-[kappa]B signaling pathway in B-lymphocytes.
The classical example is X-linked agammaglobulinemia, in which disease-causing variants in the gene (BTK, Bruton agammaglobulinemia tyrosine kinase) coding for
Bruton's tyrosine kinase lead to arrest of B-cell development at the pre-B-cell stage (2).
Mutation of unique region of
Bruton's tyrosine kinase in immunodeficient XID mice.
It is an oral, highly selective inhibitor of
Bruton's tyrosine kinase (BTK) which is important in the development and functioning of various immune cells including B lymphocytes and macrophages.
(NASDAQ: ARQL) has presented preliminary results from the company's phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant
Bruton's tyrosine kinase in patients with relapsed or refractory hematologic malignancies at the 2019 European Hematology Association annual meeting in Amsterdam, the Netherlands, the company said.
TG Therapeutics announced the publication of results from the multicenter Phase 1 triple combination trial of ublituximab, the company's anti-CD20 monoclonal antibody, umbralisib, the company's oral once-daily PI3K delta inhibitor and ibrutinib, the oral
Bruton's tyrosine kinase inhibitor, in The Lancet Haematology.
The product is a first-in-class
Bruton's tyrosine kinase inhibitor jointly developed and commercialised by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech Inc (Janssen).